Filters
Other countries
Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
---|---|---|---|
PRICKLE1 - NGS including CNV analysis Centogene AG - the Rare Disease Company Germany | 1 | 1 |
|
Centogene AG - the Rare Disease Company Germany | 1886 | 1858 |
|
Centogene AG - the Rare Disease Company Germany | 734 | 744 |
|
Centogene AG - the Rare Disease Company Germany | 777 | 770 |
|
Centogene AG - the Rare Disease Company Germany | 669 | 688 |
|
Ataxia / Spastic Paraplegia Comprehensive Panel Centogene AG - the Rare Disease Company Germany | 451 | 452 |
|
Ataxia / Spastic Paraplegia Panel Centogene AG - the Rare Disease Company Germany | 442 | 443 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
MNG Laboratories (Medical Neurogenetics, LLC.) United States | 414 | 800 |
|
Complete epilepsy panel. NGS panel of 283 genes. Genologica Medica Spain | 409 | 283 |
|
Neuronal ceroid lipofuscinosis and progressive myoclonic epilepsy panel. 31-gene NGS panel. Genologica Medica Spain | 46 | 31 |
|
Myoclonic Epilepsy (NGS Panel and Copy Number Analysis) MNG Laboratories (Medical Neurogenetics, LLC.) United States | 14 | 125 |
|
CNH Molecular Diagnostics Laboratory Childrens National Hospital United States | 132 | 83 |
|
Epilepsy, progressive myoclonic: Full gene sequencing panel CEN4GEN Institute for Genomics and Molecular Diagnostics Canada | 11 | 11 |
|
Fulgent Genetics United States | 354 | 209 |
|
Fulgent Genetics United States | 509 | 275 |
|
Progressive Myoclonic Epilepsy NGS Panel Fulgent Genetics United States | 36 | 17 |
|
PRICKLE1-Related Progressive Myoclonus Epilepsy with Ataxia: gene sequencing CEN4GEN Institute for Genomics and Molecular Diagnostics Canada | 1 | 1 |
|
Epilepsy Advanced Sequencing and CNV Evaluation Athena Diagnostics United States | 233 | 234 |
|
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.